We are committed to finding a cure for WM.

Did you know?

 

Welcome to the Waldenstrom’s Macroglobulinemia Foundation of Canada (WMFC)

If you have been diagnosed with Waldenstrom’s Macroglobulinemia (WM) or care for someone who has, welcome to the WMFC family of WM patients, caregivers, friends and relatives. We are a community providing support, research and information on WM.

Sign up for our newsletter below to receive updated information.

 

Information for the newly diagnosed

Article: Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia

https://www.cancertherapyadvisor.com/hematologic-cancers/waldenstrom-macroglobulinemia-lower-dosage-intensity-shorter-survival/article/767850/ Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia James Nam, PharmD May 22, 2018 Share this content: Decreasing the dose intensity (DI) of ibrutinib mayRead More

Article: High Rates of Response, Survival With Ibrutinib Plus Rituximab in Waldenström Macroglobulinemia

High Rates of Response, Survival With Ibrutinib Plus Rituximab in Waldenström Macroglobulinemia Saturday, June 2, 2018 Treatment with a combination of ibrutinib and rituximab improved progression-free survival (PFS) over rituximabRead More

Article: Should the General Population Be Screened for MGUS?

Should the General Population Be Screened for MGUS? Patients with particular abnormal proteins in their blood — a condition known as monoclonal gammopathies of undetermined significance (MGUS) — have aRead More

Article: Ixazomib, Dexamethasone, and Rituximab: Promising for Waldenstrom Macroglobulinemia

https://www.cancertherapyadvisor.com/lymphoma/waldenstrom-macroglobulinemia-ixazomib-dex-rituximab-treatment/article/761502/ Ixazomib, Dexamethasone, and Rituximab: Promising for Waldenstrom Macroglobulinemia James Nam, PharmD April 26, 2018 Share this content: Ixazomib, dexamethasone, and rituximab (IDR) may be a safe and effective combinationRead More

Subscribe to our newsletter